XT
DNTH icon

XTX Topco’s Dianthus Therapeutics DNTH Stock Holding History

XTX Topco’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,047
Closed -$1.09M – 4261
2026
Q1 		$1.09M Sell
13,047
-295
-2% -$17.1K 0.02% 1337
2025
Q4 		$550K Buy
+13,342
New +$517K 0.01% 1508
2025
Q3 		– Sell
-27,003
Closed -$503K – 2715
2025
Q2 		$503K Buy
+27,003
New +$507K 0.02% 1099
2024
Q2 		– Sell
-7,219
Closed -$217K – 1994
2024
Q1 		$217K Buy
+7,219
New +$157K 0.03% 1116
2023
Q3 		– Sell
-1,683
Closed -$20.4K – 1658
2023
Q2 		$20.4K Buy
+1,683
New +$19.1K ﹤0.01% 1319

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

XTX Topco's DNTH Position: Q2 2026 in Review

XTX Topco sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 13,047 shares — an estimated $1.09M sold.

XTX Topco first reported a position in DNTH in Q2 2023 and held it in 5 quarters. The position peaked at $1.09M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • XTX Topco reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 13,047 Dianthus Therapeutics shares in Q2 2026, an estimated $1.09M.
  • XTX Topco first reported a position in Dianthus Therapeutics in Q2 2023 and held it in 5 quarters.
  • XTX Topco's Dianthus Therapeutics position peaked at $1.09M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.